Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics

Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics

Glioblastoma is the most common and aggressive brain tumor, associated with poor prognosis and survival, representing a challenging medical issue for neurooncologists. Dysregulation of histone-modifying enzymes (HDACs) is commonly identified in many tumors and has been linked to cancer proliferation...

Full description

Bibliographic Details
Main Authors:	Lorenzo Taiarol, Chiara Bigogno, Silvia Sesana, Marcelo Kravicz, Francesca Viale, Eleonora Pozzi, Laura Monza, Valentina Alda Carozzi, Cristina Meregalli, Silvia Valtorta, Rosa Maria Moresco, Marcus Koch, Federica Barbugian, Laura Russo, Giulio Dondio, Christian Steinkühler, Francesca Re
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Series:	Cancers
Subjects:	glioblastoma liposomes HDAC inhibitor brain cancer
Online Access:	https://www.mdpi.com/2072-6694/14/12/2978

Similar Items

Dual Blockade of Misfolded Alpha-Sarcoglycan Degradation by Bortezomib and Givinostat Combination
by: Lucile Hoch, et al.
Published: (2022-04-01)

The pan HDAC inhibitor Givinostat improves muscle function and histological parameters in two Duchenne muscular dystrophy murine models expressing different haplotypes of the LTBP4 gene
by: Simonetta Andrea Licandro, et al.
Published: (2021-07-01)

Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
by: Adriana Celesia, et al.
Published: (2023-05-01)

The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis
by: Adriana Celesia, et al.
Published: (2022-08-01)

Analysis of Givinostat/ITF2357 Treatment in a Rat Model of Neonatal Hypoxic-Ischemic Brain Damage
by: Paulina Pawelec, et al.
Published: (2022-07-01)

Inhibition of Class I Histone Deacetylase Activity Blocks the Induction of TNFAIP3 Both Directly and Indirectly via the Suppression of Endogenous TNF-α
by: Tiziana Schioppa, et al.
Published: (2022-08-01)

HDACi: The Columbus’ Egg in Improving Cancer Treatment and Reducing Neurotoxicity?
by: Angelica Squarzoni, et al.
Published: (2022-10-01)

Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat
by: Silvia Consalvi, et al.
Published: (2013-03-01)

Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group
by: Pasquale Linciano, et al.
Published: (2021-01-01)

Synergistic Power of Piceatannol and/or Vitamin D in Bleomycin-Induced Pulmonary Fibrosis In Vivo: A Preliminary Study
by: Nehal Ezz Eldeen, et al.
Published: (2023-09-01)

Givinostat for Becker muscular dystrophy: A randomized, placebo-controlled, double-blind study
by: Giacomo P. Comi, et al.
Published: (2023-01-01)

Histone deacetylases and their inhibition in Candida species
by: Cecile Garnaud, et al.
Published: (2016-08-01)

Homologies entre les deux rétrovirus BLV et HTLV-1 et développement d’une nouvelle approche thérapeutique basée sur la levée de la latence virale
by: Nicolas Gillet, et al.
Published: (2007-01-01)

Histone deacetylase inhibitor givinostat has ameliorative effect in the colitis model
by: Cengiz Dibekoğlu, et al.
Published: (2022-07-01)

<i>N</i><sup>4</sup>-(2-Amino-4-fluorophenyl)-<i>N</i><sup>1</sup>-(3-{2-[2-(3-{[2-(2,6-dioxo-3-piperidyl)-1,3-dioxoisoindolin-4-yl]amino}propoxy)ethoxy]ethoxy}propyl)terephthalamide
by: Mohamed Abdelsalam, et al.
Published: (2022-11-01)

The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention
by: Rahma K. Alseksek, et al.
Published: (2022-07-01)

The Role of HDACs and HDACi in Cartilage and Osteoarthritis
by: He Zhang, et al.
Published: (2020-09-01)

Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
by: Hany S. Ibrahim, et al.
Published: (2021-12-01)

Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors
by: Delcuve Geneviève P, et al.
Published: (2012-03-01)

The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells
by: Laura Urwanisch, et al.
Published: (2023-02-01)

Apocynin Prevents Anxiety-Like Behavior and Histone Deacetylases Overexpression Induced by Sub-Chronic Stress in Mice
by: Silvia S. Barbieri, et al.
Published: (2021-06-01)

Suberoylanilide Hydroxamic Acid Analogs with Heteroaryl Amide Group and Different Chain Length: Synthesis and Effect on Histone Deacetylase
by: Gabriele Micheletti, et al.
Published: (2024-01-01)

Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors
by: Emre F. Bülbül, et al.
Published: (2022-04-01)

Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells
by: Christian Schrenk, et al.
Published: (2023-03-01)

Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
by: Giorgio Milazzo, et al.
Published: (2020-05-01)

Pathological Role of HDAC8: Cancer and Beyond
by: Ji Yoon Kim, et al.
Published: (2022-10-01)

Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy
by: Nisha Holay, et al.
Published: (2023-09-01)

HDAC-an important target for improving tumor radiotherapy resistance
by: Rui Ling, et al.
Published: (2023-07-01)

X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer
by: Han Yang, et al.
Published: (2012-10-01)

Histone Deacetylase Inhibitor Trichostatin A Reduces Endothelial Cell Proliferation by Suppressing STAT5A-Related Gene Transcription
by: Yize Li, et al.
Published: (2021-09-01)

A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients
by: Sara Rossi, et al.
Published: (2024-05-01)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
by: Christian Mayr, et al.
Published: (2021-07-01)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
by: Elizabeth A. Thomas
Published: (2014-05-01)

Raman Spectroscopy Characterization of Multi-Functionalized Liposomes as Drug-Delivery Systems for Neurological Disorders
by: Francesca Rodà, et al.
Published: (2023-02-01)

Histone Deacetylases Function in the Control of Early Hematopoiesis and Erythropoiesis
by: Pascal Vong, et al.
Published: (2022-08-01)

Microglial Expression of Hdac1 and Hdac2 is Dispensable for Experimental Autoimmune Encephalomyelitis (EAE) Progression
by: Moumita Datta, et al.
Published: (2020-10-01)

HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights
by: Eugenia Passaro, et al.
Published: (2021-12-01)

Methionine 274 Is Not the Determining Factor for Selective Inhibition of Histone Deacetylase 8 (HDAC8) by L-Shaped Inhibitors
by: Niklas Jänsch, et al.
Published: (2022-10-01)

Essential roles of HDAC1 and 2 in lineage development and genome-wide DNA methylation during mouse preimplantation development
by: Panpan Zhao, et al.
Published: (2020-04-01)

New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
by: Yi Luan, et al.
Published: (2022-04-01)